13.06.2024 • NewsBioprocessingbiologicsinvestment

Kyowa Kirin to Establish New Biologics Manufacturing Plant in US

Kyowa Kirin announced a new, state-of-the-art manufacturing facility in Sanford, North Carolina, US. Kyowa Kirin will invest up to $530 million (€489 million) in constructing a 15,951m2 two-bioreactor facility, scheduled to break ground in Q3 of 2024.

The new facility will accelerate Kyowa Kirin’s development and production of biologic therapies for patients with debilitating diseases with unmet medical needs.

“I am very excited to announce that Kyowa Kirin decided to construct a new manufacturing plant for biologics drug substance in the United States,” said Toshiyuki Kurata, Chief Supply Chain Officer, and Global Manufacturing Head at Kyowa Kirin. “The new facility will be scalable with our Takasaki Plant, to help ease technology transfer between the two plants and add production capacity. We believe this will help accelerate drug development and production.”

The new facility will manufacture innovative biologic therapies, including next-generation antibodies, for Kyowa Kirin’s planned clinical trials and future commercial use. It will create more resilient and efficient supply lines that can readily withstand shifting global forces. Additional land will allow for future expansion, should the company’s portfolio necessitate greater capacity as its pipeline programs advance.

Digital representation of Kyowa Kirins new biologics manufacturing plant in...
Digital representation of Kyowa Kirin's new biologics manufacturing plant in North Carolina. © Kyowa Kirin

The Sanford facility will round out Kyowa Kirin’s global manufacturing network, which includes sites in Takasaki City, Gunma Prefecture, and Ube City, Yamaguchi Prefecture in Japan. The new facility will build upon the manufacturing methods and technologies in the Takasaki plant to further enhance the company’s productivity and efficiency. By locating its new site in North Carolina’s robust life sciences hub, Kyowa Kirin will benefit from a network of biomanufacturing resources.

Company

Kyowa Kirin Co., Ltd.


Tokyo
Japan

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.